Daratumumab
- Generic Name
- Daratumumab
- Brand Names
- Darzalex, Darzalex Faspro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 945721-28-8
- Unique Ingredient Identifier
- 4Z63YK6E0E
- Background
Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind.
...
- Indication
Daratumumab is indicated as an intravenous injection alone or in combination with other medications for the treatment of multiple myeloma. It is available as a combination product with hyaluronidase for the treatment of adults with multiple myeloma as monotherapy or combination therapy and light chain amyloidosis in combination with other drugs.
- Associated Conditions
- Multiple Myeloma (MM), Primary Amyloidosis, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy
- Conditions
- Interventions
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 57
- Registration Number
- NCT04140162
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸University of Texas Southwestern -- Simmons Comprehensive Cancer Center, Dallas, Texas, United States
🇺🇸University of Rochester, Rochester, New York, United States
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- AIDS Malignancy Consortium
- Target Recruit Count
- 15
- Registration Number
- NCT04139304
- Locations
- 🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT04136756
- Locations
- 🇺🇸
Western Regional Medical Center - CTCA, Goodyear, Arizona, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸New York Medical College, Valhalla, New York, United States
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 237
- Registration Number
- NCT04133636
- Locations
- 🇺🇸
Virginia Commonwealth University - Massey Cancer Center, Richmond, Virginia, United States
🇺🇸University Of California San Diego, San Diego, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 40
- Registration Number
- NCT04131309
- Locations
- 🇳🇱
UMCU, Utrecht, Netherlands
🇮🇹University Hospital San Matteo, Pavia, Italy
🇫🇷Hopital De Rangueil CHU, Toulouse, France
A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Fondazione EMN Italy Onlus
- Target Recruit Count
- 45
- Registration Number
- NCT04124497
- Locations
- 🇮🇹
Ospedali Riuniti, Bergamo, Italy
🇮🇹Istituto Clinico Humanitas, Rozzano, Italy
🇮🇹Policlinico Universitario di Udine, Udine, Italy
A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma
- First Posted Date
- 2019-10-09
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 21
- Registration Number
- NCT04121260
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
🇨🇳The Third Xiangya Hospital, Central South University, Changsha, China
🇨🇳Nanfang Hospital, Guangzhou, China
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 290
- Registration Number
- NCT04108195
- Locations
- 🇨🇦
Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California, United States
Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation
- Conditions
- Interventions
- First Posted Date
- 2019-09-13
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- Ronald Witteles
- Registration Number
- NCT04088903
Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients
- Conditions
- Interventions
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- Tel-Aviv Sourasky Medical Center
- Target Recruit Count
- 41
- Registration Number
- NCT04065789
- Locations
- 🇮🇱
Hematology Department Sourasky Medical Center, Tel Aviv, Israel
🇮🇱Soroka Medical Center, Be'er Sheva, Israel
🇮🇱Kaplan Medical center, Reẖovot, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.